Search
- Feb 15
Wedbush analyst David Nierengarten joins BiotechTV for Analyst Thursdays from San Francisco
David Nierengarten gives his take on biotech and discusses Blueprint Medicines, G1 Therapeutics, Y-mAbs, Fusion Pharma, and more.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A